Praxis Precision Medicines
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an ...
Latest News
15 hours ago · seekingalpha.com
Praxis Precision Medicines, Inc. (PRAX) Presents at UBS Global Biopharma Conference 2026 TranscriptPraxis Precision Medicines, Inc. ( PRAX ) UBS Global Biopharma Conference 2026 November 16, 2026 5:40 AM EST Company Participants Marcio Souza - President, CEO & Director Conference Call Participants Joon Lee - UBS Investment Bank, Research Division Presentation Joon Lee UBS Investment Bank, Research Division Okay. Well, thank you, everyone, for joining us for this inaugural UBS Global Biopharma Conference.
21 hours ago · seekingalpha.com
Praxis Precision Medicines: No Material Changes After Q3 And Investor Day (Rating Kept)I maintain a Strong Buy on Praxis Precision Medicines, with a $601 fair value, 85% above the November 12 close. The valuation falls from $664 primarily after correcting the share count for pre-funded warrants and options; lower net cash also reduces value. Ulixacaltamide is the principal risk: its January FDA decision moves modeled value to $679 on approval or $159 on a complete response letter.
5 days ago · seekingalpha.com
Praxis Precision Medicines, Inc. (PRAX) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference TranscriptPraxis Precision Medicines, Inc. ( PRAX ) 3rd Annual Guggenheim Healthcare Innovation Conference November 9, 2026 9:30 AM EST Company Participants Marcio Souza - President, CEO & Director Tim Kelly - CFO & Treasurer Conference Call Participants Yatin Suneja - Guggenheim Securities, LLC, Research Division Presentation Yatin Suneja Guggenheim Securities, LLC, Research Division All right. I think we're live now.
8 days ago · globenewswire.com
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsFDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing Topline results from the EMERALD study of relutrigine in broad developmental and epileptic encephalopathies (DEEs) expected in the fourth quarter of 2026 Cash and investments of approximately $1.3 billion as of September 30, 2026 maintain runway into 2028 Praxis to host an in-person and virtual Investor Day on November 12, 2026 and will participate in a fireside chat at the Guggenheim Biotech Summit today, November 9 at 9:30am ( register here ) BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today provided a corporate update and reported financial results for the third quarter of 2026. “We are entering a defining period for Praxis, with two key regulatory milestones ahead and the opportunity to become a commercial CNS company.
20 days ago · globenewswire.com
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference ParticipationBOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report financial results for the third quarter ended September 30, 2026, before the financial markets open on Monday, November 9, 2026. The Company also announced details of its upcoming Investor Day and participation in November investor conferences.
3 months ago · seekingalpha.com
Praxis: Commercial Launch Could Smash Expectations (Video)Prax is analyzed using a sum-of-parts valuation approach, focusing on its lead asset, Ulixa. Recent updates from the Goldman Sachs presentation highlight key developments ahead of Ulixa's commercial launch. I assess PRAX's strategic positioning and upcoming catalysts tied to Ulixa's market entry.
3 months ago · seekingalpha.com
Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call TranscriptPraxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript
3 months ago · marketbeat.com
Praxis Precision Medicines Q2 Earnings Call HighlightsPraxis Precision Medicines NASDAQ: PRAX said it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies, or DEEs, as both new drug applications remain under FDA review.
4 months ago · globenewswire.com
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the second quarter ended June 30, 2026 and provide a corporate update, before the financial markets open on Thursday, August 6, 2026.
4 months ago · seekingalpha.com
Praxis Precision Medicines: Priced For Half Of What I Think It's WorthPraxis Precision Medicines: Priced For Half Of What I Think It's Worth
Analyst Summary
Add to Watchlist
Select watchlists to add or remove PRAX